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Executive Summary 
  
Prescription drug monitoring programs (PDMPs) are state policy tools to combat risky 
opioid prescribing. Since 2012, several states began to mandate PDMP use. As mandating use 
laws have settled down, evaluating potential adverse events becomes possible.  
In this study, I focus on alcohol-induced mortality as a potential unintended consequence 
via substituting alcohol for prescription opioids, since alcohol and opioids are often concurrently 
misused as a part of pain self-management. Therefore, the aim of this study is to analyze the 
unintended consequences of prescription opioid access restrictions on alcohol-induced mortality.  
I compare the alcohol-induced mortality among adults during pre- and post-revision of 
the Kentucky PDMP from 2007 to 2017 by using a difference-in-differences design. The county-
level alcohol-induced death data was extracted from Centers for Disease Control and Prevention 
Wide-ranging Online Data for Epidemiologic Research. Missouri was chosen as a comparison 
state because state-level PDMP have not been existed.  
The finding indicated that mandating PDMP use in Kentucky did not enhance alcohol-
induced mortality. In conclusion, prescription opioid access restrictions do not appear to result in 
unintended consequences on alcohol-induced mortality for adults. Therefore, I recommend 
retaining the mandatory features of Kentucky’s PDMP. This study is the first assessment of 
alcohol-related adverse events resulting from PDMPs. Further studies should be conducted to 
evaluate the finding. 
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Introduction 
 
Opioid Crisis: Pain Management Failure 
 
During the 1990s, the healthcare system experienced a renewed focus on pain 
management. The American Pain Society and the United States Department of Veterans Affairs 
promoted pain as the ‘fifth vital sign’, along with body temperature, blood pressure, pulse, and 
respiratory rate. Then in 2001, the Joint Commission on Accreditation of Healthcare 
Organizations also adopted pain as the ‘fifth vital sign’ and certified hospitals only when pain 
assessments were conducted for all patients. These institutional policies led medical providers to 
making pain treatment a priority for patients (Christie, et al., 2017). This, coupled with several 
publications by healthcare providers who claimed little to no addictive tendencies in their 
patients after prescribing opioids—specifically a letter titled "Addiction Rare in Patients Treated 
with Narcotics (Jick, 1980)" published in the New England Journal of Medicine – led medical 
professionals toward opioids as a solution for the pain treatment. All the while, manufacturers of 
prescription opioids, including Percocet, Vicodin, and OxyContin advertised the concept that 
their medicines are safe, resulting in their prevalent use (Moghe, 2016). This frequent prescribing 
of opioids for pain management continued nationally for years and contributed as a major cause 
of the current opioid epidemic in the United States (U.S. Department of Health and Human 
Services, 2019). 
As the increased trend in opioid prescribing continued, so did deaths associated with 
prescription opioids. Nearly 218,000 deaths were caused by prescription opioids from 1999 to 
2017. The number of yearly deaths during this period rose rapidly, as the mortality rate in 2017 
was five times as great as in 1999. In 2017, 46 people died each day due to prescription opioids. 
Accordingly, among total deaths related to opioid overdose, more than 35 percent of deaths 
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involved prescription opioids. Methadone, oxycodone, and hydrocodone were the major culprit 
drugs contributing to prescription opioid overdose deaths. The highest prescription opioid 
induced deaths were in West Virginia, Maryland, Kentucky, and Utah (Centers for Disease 
Control and Prevention, 2018). The misuse of prescribed opioids is prevalent as well. About nine 
out of ten people using opioid analgesics nonmedically got the drugs from their friend/relative or 
from prescriptions for themselves (Substance Abuse and Mental Health Services Administration, 
2014). In 2017, 11.4 million people misused prescription opioids, including 2 million first-time 
misusers (U.S. Department of Health and Human Services, 2019). Although President Trump 
signed a package of bills including the Support for Patients and Communities Act to combat the 
opioid crisis in October 2018 (Lopez, 2018), most states had implemented a policy solution, 
namely, prescription drug monitoring programs, decades earlier to alleviate the financial, 
physical, and emotional strain that was resulting from the opioid crisis.  
 
Prescription Drug Monitoring Programs 
 
Prescription drug monitoring programs, or PDMPs, are state-operated programs that track 
the prescribing and dispensing of medications classified as federally controlled substances, 
including opioids (Drug Enforcement Administration, 2018). A central system collects the 
electronic prescription data, allowing only authorized users—healthcare providers, and 
occasionally law enforcement—to access it. The purpose of these programs is to support the 
detection and prevention of controlled substance misuse, abuse, and diversion. The program 
mitigates the information asymmetry issue among healthcare providers, patients, and law 
enforcement by allowing the authorized users access to patient prescription records. This 
monitoring is expected to reduce the prevalence of ‘doctor shopping’, a phenomenon whereby 
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patients obtain multiple prescriptions for controlled substances intentionally by visiting 
numerous clinics (Blumenschein, et al., 2010; Goodin, 2015). In California, doctor shopping 
occurs more often for prescription opioids than for any other controlled substances (Campbell, et 
al., 2018). 
PDMPs have been implemented throughout the United States, as early as 1939 in 
California and as late as February 1st, 2019 in four jurisdictions of Missouri. Currently, 49 states, 
the District of Columbia, Puerto Rico, Guam, and 72 jurisdictions in Missouri are operating their 
own PDMPs (Brandeis University, 2018a; Saint Louis County Public Health, 2019). While most 
PDMPs resemble the electronic database mentioned previously, operational details vary between 
the states (Blumenschein, et al., 2010). Most early PDMPs did not legally mandate prescribers to 
use the program. Consequently, the role of PDMPs in controlling prescription opioids and 
opioid-associated overdose was not as effective as their intention (Haffajee, et al., 2018; Shev, et 
al., 2018; Strickler, et al., 2019; Wen, Schackman, Aden, & Bao, 2017). As a result, over 40 
states amended or enacted their PDMPs by adding mandatory features from 2012 to January 
2019 (The Pew Charitable Trusts, 2018; Legal Science, 2016; Brandeis University, 2019). 
However, the comprehensiveness of required usage by prescribers, and sometimes dispensers as 
well, varies between the state programs.  
Several studies described comprehensive mandatory use laws as mandates for: prescriber 
enrollment, querying previous prescription opioid use history (Strickler, et al., 2019; Haffajee, et 
al., 2018; Sun, et al., 2018; Brandeis University, 2019), and comprehensive use with specific 
objective criteria (Haffajee, et al., 2018). Other important features of PDMPs include delegate 
access (Haffajee, Jena, & Weiner, 2015; The Pew Charitable Trusts, 2018), monitoring drugs in 
Schedules II to IV, more frequent data collections at regular intervals (Legal Science, 2016), and 
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sharing data with other states (Brandeis University, 2018b). Among these features, the use 
mandate was the most important factor improving PDMPs effectiveness on reducing mean 
morphine-equivalent dosage, risky opioid prescribing, Schedule II prescriptions, and 
expenditures for opioids. These studies commonly selected Kentucky, Tennessee, and New York 
as states operating robust PDMPs among the early enactors of mandatory laws (Haffajee, Jena, & 
Weiner, 2015; Haffajee, et al., 2018; Strickler, et al., 2019; Wen, Schackman, Aden, & Bao, 
2017).  
Implementation of mandatory PDMP use aroused concerns about unintended 
consequences (Haffajee, Jena, & Weiner, 2015). One possible unintended consequence from 
reduced access to prescription opioids is that individuals may seek alternative therapies to 
substitute for the opioids that they are no longer able to obtain from their physician. In some 
cases, that means the individual will seek opioids on the illicit black-market, including heroin or 
synthetic opioids. In other cases, the individual may look for psychoactive substances that are 
available legally (Islam & McRae, 2014; Columbia University, 2018). Alcohol is a legal 
psychoactive substance that may be an attractive alternative for an individual who no longer has 
access to prescription opioids. Attempts to self-medicate pain can result in unhealthy alcohol 
consumption (Atkinson R. M., 1990a; Atkinson, Tolson, & Turner, 1990b). Alcohol is often used 
with opioids concurrently to induce early onset of psychoactive (euphoric) effects (Maldonado, 
2018; Gudin, Mogali, Jones, & Comer, 2013). Several studies argued that drinking alcohol leads 
to endogenous opioid release in humans and rodents (Mitchell, Marks, Jagust, & Fields, 2012; 
Gianoulakis, 2001), which implies opioid abusers could rely on more alcohol consumption to 
simulate opioid use when they cannot access opioids. Therefore, the aim of this study is to 
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evaluate the substitution effect, or unintended consequences, of the PDMP use mandate 
implementation on alcohol-induced mortality.  
 
Literature Review 
 
Several studies have evaluated the early PDMPs. The opioid supply decreased in PDMP-
implemented states compared to non-implemented states from 1997 to 2003 according to Drug 
Enforcement Administration (DEA) data. On the other hand, PDMP implementation had no 
association with lowering opioid consumption and overdose mortality rates during 1999 to 2005 
in other DEA analyses (Paulozzi, Kilbourne, & Desai, 2011). In 2002, the U.S. Government 
Accountability Office also reported that implementing PDMPs reduced the number of 
investigation days that law enforcement officials required to detect doctor shopping in Kentucky, 
which was 156 days on average before implementation and 16 days on average after 
implementation (U.S. General Accounting Office, 2002).  
Previous studies examining PDMPs show varying impacts. Several studies have been 
conducted comparing states with PDMPs versus those without, specifically for Medicare Part D 
participants. Between 2007 and 2012, states with PDMPs showed a decrease in opioid use 
(Moyo, et al., 2017), while another examination between 2010 and 2013 revealed modest effects 
on oxycodone use and smaller effects on opioid use (Yarbrough, 2018). PDMP and pill mill law 
implementation in Florida also led to a reduction of prescription opioid utilization in high-risk 
patients compared to Georgia, which had less robust policies limiting opioid access (Chang, 
Murimi, Faul, Rutkow, & Alexander, 2018).  
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However, some studies suggest that PDMP implementation results in a substitution effect 
within the Drug Scheduling system – for example, a decrease in prescriptions for Schedule II 
opioids leading to an increase in prescriptions for alternative painkillers or Schedule III drugs, so 
that the overall number of prescriptions does not change significantly (Goodin, 2015; Paulozzi, 
Kilbourne, & Desai, 2011; Bao, et al., 2016). In addition, recent publications found that 
mandating PDMP use is related to reducing high-risk opioid prescriptions, and risk of 
prescription opioid-related poisoning (Bao, et al., 2018; Pauly, Slavova, Delcher, Freeman, & 
Talbert, 2018). By 2013, six states—Kentucky, New Mexico, Tennessee, New York, Vermont, 
and West Virginia—strengthened their PDMPs by mandating prescribers to register with the 
PDMP, and mandating comprehensive use of the program (Haffajee, et al., 2018). 
A number of studies have investigated outcomes associated with PDMPs, and as 
described above, findings are mixed. Surprisingly, no robust evaluation of the unintended 
consequences of PDMPs currently exists. While PDMPs could be a policy solution for the 
current prescription opioid problem, it is important to gauge the potentially harmful outcomes 
that may result from their implementation. 
 
 
Objective and Hypothesis 
 
The goal of this project is to evaluate the potential adverse effect on alcohol-induced 
mortality of prescription opioid restriction policy executed by mandating the use of PDMPs. In 
this analysis, the outcome measure is specified as the change of alcohol-induced mortality among 
Kentucky counties. Therefore, I hypothesized that the PDMP use mandate introduced in mid-
2012 increased alcohol-induced mortality in Kentucky counties after the implementation.  
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Research Design 
 
The aim of this study is to compare the alcohol-induced death rate between pre- and post-
2012 revision of the Kentucky PDMP from 2007 to 2017 by using a difference-in-differences 
design compared with a neighboring state, Missouri, where a state-wide PDMP did not exist. The 
difference-in-differences design evaluates the causal effect of a policy change on the outcome of 
interest by comparing a policy-implementation group with a non-implementation group. This 
analysis observed aggregated county-level data for the time period before and after 
implementation. Data are annual.  
 
State Selection 
 
As mentioned above, Kentucky has operated an early, robust PDMP. Thus, Kentucky was 
selected as a treatment state in this study. According to the Kentucky House Bill 1 (KyHB1), 
prescribers and dispensers were mandated to register with the state’s PDMP and prescribers must 
query the PDMP before prescribing opioids as of July 20, 2012 (Kentucky Revised Statutes 
218A, 172). The policy change was immediately adopted by practitioners. In 2012, the 
compliance rate of prescriber registration among DEA (Drug Enforcement Administration) 
registered practitioners went up from approximately 35% to 93% after the implementation. 
Moreover, the total number of queries increased more than four times after the implementation in 
the same year (Freeman, Goodin, Troske, & Talbert, 2015). 
I selected Missouri as a neighboring comparison state because it did not operate a state-
level PDMP during the time period. In addition, alcohol sales policy in Missouri has been 
consistent throughout all counties, which will be discussed further below.  
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Population and Data Source 
 
The targeted population was 18 years or older between the time period from 2007 to 
2017.  
The county-level mortality data was obtained from the Centers for Disease Control and 
Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER), which is a 
publicly available database. In this analysis, I used detailed mortality data, which could specify 
underlying cause of death.  
 
Measure 
 
I used alcohol-induced mortality by place of residence in Kentucky and Missouri counties 
among people age 18 or more during 2007 to 2017. CDC WONDER uses the definition of 
‘alcohol-induced causes’ from the National Center for Health Statistics to identify alcohol-
induced mortality (Centers for Disease Control and Prevention, 2018). The definitions for 
‘alcohol-induced causes’ are made using the International Statistical Classification of Diseases 
and Related Health Problems, 10th revision (ICD-10) codes, which is used to categorize cause of 
death by the World Health Organization. Detailed ICD-10 codes involved in this study are 
presented in Table 1.  
The death rate was calculated as the number of deaths per 100,000 people and was 
transformed into logarithms so that estimated effects are approximately percentage changes. 
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Table 1. ICD-10 codes for alcohol-induced causes 
Underlying Cause of death ICD-10 code 
Alcohol-induced pseudo-Cushing syndrome E24.4 
Mental and behavioural disorders due to use of alcohol, acute intoxication F10.0 
Mental and behavioural disorders due to use of alcohol, harmful use F10.1 
Mental and behavioural disorders due to use of alcohol, dependence syndrome F10.2 
Mental and behavioural disorders due to use of alcohol, withdrawal state F10.3 
Mental and behavioural disorders due to use of alcohol, withdrawal state with delirium F10.4 
Mental and behavioural disorders due to use of alcohol, psychotic disorder F10.5 
Mental and behavioural disorders due to use of alcohol, amnesic syndrome F10.6 
Mental and behavioural disorders due to use of alcohol, residual and late-onset psychotic disorder F10.7 
Mental and behavioural disorders due to use of alcohol, other mental and behavioural disorders F10.8 
Mental and behavioural disorders due to use of alcohol, unspecified mental and behavioural disorder F10.9 
Degeneration of nervous system due to alcohol G31.2 
Alcoholic polyneuropathy G62.1 
Alcoholic myopathy G72.1 
Alcoholic cardiomyopathy I42.6 
Alcoholic gastritis K29.2 
Alcoholic fatty liver K70.0 
Alcoholic hepatitis K70.1 
Alcoholic fibrosis and sclerosis of liver K70.2 
Alcoholic cirrhosis of liver K70.3 
Alcoholic hepatic failure K70.4 
Alcoholic liver disease, unspecified K70.9 
Alcohol-induced acute pancreatitis K85.2 
Alcohol-induced chronic pancreatitis K86.0 
Finding of alcohol in blood R78.0 
Accidental poisoning by and exposure to alcohol X45 
Intentional self-poisoning by and exposure to alcohol X65 
Poisoning by and exposure to alcohol, undetermined intent Y15 
 
  
 13 
Covariates 
 
 The policy was implemented in the middle of 2012, therefore, the years after 2012 (Post) 
were coded as “1”, otherwise years are coded as “0”. I considered the latter part of 2012 as a lag-
phase of the policy effect and coded it as “0”. The treatment state (TS) was coded as “1”, 
otherwise “0”. The variable indicating the policy implementation in Kentucky was expressed as 
an interaction (TS ´ Post) and was coded as “1” after 2012, otherwise “0”, i.e. the difference-in-
differences. Population by county (Pop) was included in the analysis. The population was 
expressed per 100,000 people. In CDC WONDER data, if the death count is less than 20, those 
crude death rates, which are automatically calculated, are shown as ‘unreliable’ (Centers for 
Disease Control and Prevention, 2018). Since the death rate was re-calculated with the raw 
number, unreliable variable (Unrel) were coded as “1” with all other observations coded as “0” 
to control potential reporting bias or other biases due to small observations. 
Alcohol sales regulation policy that could be potentially interacting with PDMP was 
considered in this analysis. Some states have different alcohol sales regulations among counties. 
Kentucky operates by county-level, or even smaller jurisdictions such as towns or cities, based 
on votes and categorized dry, wet, and moist. Dry counties do not allow the sale of alcohol at all, 
whereas wet counties permit alcohol sales with minimal restrictions uniformly. Besides dry or 
wet policies, all the other counties are classified as ‘moist’, which allow the sale of alcohol in 
certain designated locations and/or situations (NABCA Research, 2016). This restricted 
accessibility to alcohol in dry or moist counties could lower the substitution effect and limit the 
alcohol use. Therefore, since the variation of alcohol regulations could affect the outcomes of 
interest, alcohol sales policy is included as one of covariates in this research design. Kentucky 
Alcoholic Beverage Control kindly provided the voting results of alcohol sales regulations from 
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each jurisdiction between 2007 and 2015 and also posted the legal status of each jurisdiction on 
their website from 2016 to 2017 (Estep, 2016; Kentucky Alcoholic Beverage Control, 2017). 
Unfortunately, because of the limitation of data from CDC WONDER, counties with dry alcohol 
policies in Kentucky were not included (i.e., there were too few alcohol-induced deaths in these 
Kentucky counties to permit public reporting. This will be discussed below). The alcohol sales 
regulations in Missouri counties were uniformly wet policy since 1934 (Missouri Drpartment of 
Public Safety, 2019). Uniform alcohol sales policy combined with a lack of state-level PDMP 
makes Missouri an excellent candidate to use as a control state. Thus, given the limitations of the 
mortality data, moist counties (Alc) were coded as “1”, and wet counties were coded as “0  
 
Statistical Analysis 
 
 The regression model of the difference-in-differences design is shown below:  
𝑌"#$ = 𝛼' + 𝛼)𝑇𝑆" + 𝛼,𝑃𝑜𝑠𝑡$ + 𝛼1(𝑇𝑆 × 𝑃𝑜𝑠𝑡)"$ + 𝛼5𝐴𝑙𝑐#$ + 𝛼9𝑃𝑜𝑝#$ + 𝛼;𝑈𝑛𝑟𝑒𝑙#$ + 𝑒"#$ 
The dependent variable 𝑌"#$, is the measure of alcohol-induced mortality for county j in 
state i at year t; 𝛼' is a constant term of this model, representing the expected mean value of 𝑌"#$. 
The covariates mentioned above were all included as independent variables in the model. TS 
indicates treatment state i, and Post specifies a post-policy period at year t; 𝛼1 represents the 
difference-in-differences estimator, which captures the overall secular trend of alcohol-induced 
mortality for state i. Alc, Pop, and Unrel are indicators for the alcohol sales policy, population 
per 100,000 people, and unreliable crude death rate, respectively, in county j at year t. The 
random unobserved error term is 𝑒"#$, including all that is omitted or unobserved. The statistical 
analysis was executed using Stata v13.1. All the coefficients were estimated through a linear 
regression analysis and the estimation is heteroscedasticity-consistent.   
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Results 
  
The robust PDMP in Kentucky did not increase alcohol-induced mortality significantly. 
The alcohol-induced death rates are higher in Kentucky than in Missouri and are increasing in 
both Kentucky and Missouri after the policy change. Nonetheless, there is no evidence to reject 
the null hypothesis that the robust PDMP does not increase the alcohol-induced death rates in 
Kentucky. 
 
Sample Characteristics 
 
Total 146 counties were observed regarding alcohol-induced mortality in the difference-
in-differences analysis of the adult population residing in Kentucky and Missouri from 2007 to 
2017 (Table 2). In detail, Kentucky observations accounted for 40% (n=58), which is 13 counties 
among total 120 counties (11%; Table 3). Counties that were observed each year during the 
whole time period were Fayette, Jefferson, and Kenton. These counties include or are located 
around big cities, which are Lexington, Louisville, and Cincinnati. Meanwhile, Missouri 
amounted to the rest of the observations (60%; n=88), which contained 15 counties out of 114 
counties (13%). The most frequently observed counties for 11-year timeframe were Clay, 
Greene, Jackson, St. Louis City, and St. Louis, where they are, or they possess, or they are near 
big cities such as Kansas City or Springfield. Among these observations, approximately 42% of 
the counties (n=61) exhibited unreliable crude death rates. Four Kentucky counties – Hardin 
(n=5), Madison (n=1), Pulaski (n=1), and Warren (n=1) – had moist alcohol sales laws for at 
least one year in the time period. All the counties that had less than 100,000 residents in both 
states had less than 20 alcohol-induced deaths. Some time-points in five counties – Kenton 
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(Kentucky), Boone (Missouri, MO), Clay (MO), Jefferson (MO), and St. Charles (MO) – 
showed unreliable crude mortalities. 
 
 
Table 2. The number of counties collected to measure alcohol-induced mortality from 2007 
to 2017 
Year Kentucky Missouri Total 
2007 3 6 9 
2008 4 8 12 
2009 7 6 13 
2010 4 5 9 
2011 5 7 12 
2012 5 8 13 
2013 4 9 13 
2014 5 9 14 
2015 6 10 16 
2016 7 10 17 
2017 8 10 18 
Total 58 88 146 
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Table 3. List of counties involved in the outcome of alcohol-induced mortality from 2007 to 
2017 
Kentucky Counties Frequency  Missouri Counties Frequency 
Boone County 3  Boone County 4 
Bullitt County 2  Buchanan County 4 
Campbell County 4  Butler County 2 
Clark County 1  Camden County 1 
Daviess County 6  Cass County 1 
Fayette County 11  Clay County 11 
Hardin County 5  Franklin County 1 
Jefferson County 11  Greene County 11 
Kenton County 11  Jackson County 11 
Madison County 1  Jasper County 1 
Meade County 1  Jefferson County 8 
Pulaski County 1  Platte County 2 
Warren County 1  St. Charles County 9 
Total 58  St. Louis city 11 
   St. Louis County 11 
   Total 88 
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Effect of robust PDMPs on alcohol-induced mortality  
 
In the difference-in-differences model (Table 3; F=22.09; p<0.001), the shift of alcohol-
induced mortality after restricting prescription opioid use through mandating PDMP use was not 
statistically significant (p>0.05) among adults residing in Kentucky compared to Missouri.  
 
 
 
Table 4. Alcohol-induced mortality outcomes of robust PDMP implementation among 
adults living in Kentucky (treatment state) compare to Missouri (control state). 
 Alcohol-Induced Mortality (%) 
Covariates Estimates 
Robust  
Standard Error 
Difference-in-differences 14.49 10.50 
Treatment State (vs. Control State) 17.32 7.72* 
Post-Policy (vs. Pre-Policy) 16.19 7.37* 
Moist Counties (vs. Wet Counties) -5.55 10.06 
Population (Per 100,000) -11.85 1.29** 
Counties with Unreliable Mortality -34.19 7.05** 
*p<0.05, **p<0.001 
 
 
Change in alcohol-induced mortality from 2007 to 2017 
 
The average mortality in Kentucky was significantly 17.3% higher than Missouri during 
the entire time period when other things remain equal (Table 4; p<0.05). As shown in Figure 1, 
the average mortality in Kentucky was always higher than Missouri, except the year 2008. The 
overall mortality trend was positively associated with time in each state, Kentucky (correlation 
coefficient, ρ=0.40) and Missouri (ρ=0.25). When comparing the mortality in both states before 
and after the policy change in 2012, the post-policy period had 16.2% higher death rate than the 
pre-policy period while everything else stays equal (p<0.05). The counties with moist alcohol 
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sales policy did not show any significant results on the mortality change compare to those with 
the wet policy. When population in a county increased by 100,000 people, the alcohol-induced 
death rate decreased by 11.8% on average while holding other conditions equal (p<0.001). The 
counties that had less than 20 count of deaths showed 34.2% lower death rate on average than the 
other counties (p<0.001).  
 
 
Figure 1. Trend in average alcohol-induced mortality among adults living in Kentucky 
(treatment state) and Missouri (control state) between 2007 and 2017.  
 
*Kentucky House Bill 1 was implemented in 2012 (red line). 
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Discussion 
 
 I evaluated the alteration of alcohol-induced mortality after implementing PDMP use 
mandate in Kentucky. The finding suggested that the causal effect of comprehensive PDMP in 
Kentucky was not statistically significant in changing alcohol-induced deaths among the adult 
population. The alcohol-induced mortality in Kentucky was mostly greater than that in Missouri. 
Each state had an increase trend in alcohol-induced mortality over time period, therefore, the 
mortality in the post-policy period for both states was greater than that in the pre-policy period. 
This increase trend of crude mortality corresponds with the national increasing trend since 2010 
(Xu, Murphy, Kochanek, Bastian, & Arias, 2018). Regardless of these trends, the trajectory of 
outcomes from Kentucky did not diverge significantly from Missouri.  
It could be possible that the policy change had an effect on maintaining the status quo of 
alcohol-induced mortality. Instead of depending on alcohol use, people could substitute illicit 
opioids or other alternative substances. The heterogeneous response toward the policy change 
could also generate non-significant result. For example, appropriate pain management guidance 
from practitioners using Kentucky PDMP could mute the increase tendency of drug misusers 
substituting alcohol for prescription opioids. In addition, migration effect is neglected. 
Kentuckians could migrate to Missouri or other neighboring states without robust PDMPs to 
obtain prescription opioids without relying on alcohol use. Likewise, moist county residents 
could easily migrate to neighboring counties and generate non-significant results versus wet 
county residents. The last possible cause is that in both Kentucky and Missouri, deaths by 
alcohol have been increasing, and any effects of PDMPs may be difficult to detect within the 
increasing trends in both states. 
 21 
The control state has several concerns in serving as a counterfactual. One concern is that 
Kentucky did operate a PDMP prior to 2012, while Missouri has never had a state-wide PDMP. 
It could be better to find another comparison state that had a PDMP similar to Kentucky’s before 
2012 and has not implemented robust features. However, without a use mandate, people can 
easily find prescribers who do not use the PDMP in order to receive inappropriate prescription 
opioids, as was the case prior to KyHB1 adoption when most prescribers did not utilized the 
PDMP (Freeman, Goodin, Troske, & Talbert, 2015). Hence, I assumed both Kentucky and 
Missouri had non-treated status before 2012. Another concern is about satisfying the common 
trend assumption in difference-in-differences design. Apparently in Figure 1, similar trends are 
observed between 2009 to 2012, sharing similar upward slopes. Therefore, the common trend 
assumption is not violated in this study. One last concern is that PDMP implementation in 
Missouri started in 2017 in 43 counties (approximately a third of counties). This started on April 
25th among 14 jurisdictions and expanded gradually via those counties (Saint Louis County, 
2019). These PDMPs could be negligible since they do not uniformly cover the state, so people 
could easily travel to avoid the effect of PDMPs. 
 Larger population in a county was related to a lower percentage of mortality. This finding 
could imply potential urban-rural disparity on alcohol-induced mortality. However, Dixon and 
Chartier (2016) reviewed that urban residents tend to use more alcohol than rural residents and 
the alcohol use disorder incident trend was similar across the regions. Furthermore, adults older 
than 50 living in urban Kentucky presented higher rates of hospitalization caused by concurrent 
alcohol and medication use between 2002 and 2012 compare to those in rural area (Zanjani, et 
al., 2016). 
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Limitations 
 
This study has several limitations. Firstly, the research design might not capture the true 
causal effect of policy change. Unobserved or unconsidered variables could be the cause. Drug 
abusers could prepare for the policy change, and this is not reflected in this analysis. For 
example, they could receive excessive prescription opioids beforehand and use them instead of 
substituting alcohol. Accordingly, latency of policy adoption could be longer than the research 
design in this study, although the policy compliance rate among practitioners was quite fast. 
Another possible cause of the error is that the predicted outcome is too narrow to observe the 
hypothesis. For instance, substance misusers might be healthy enough to survive after increasing 
alcohol consumption. Also, age-adjusted mortality might be an appropriate outcome measure 
instead of the crude rate because age distribution might vary between the counties. Thus, the 
crude death rate may not represent the effect of PDMP on alcohol-induced mortality caused by 
substituting alcohol for prescription opioid use.  
Secondly, the obtained data has several defects. As mentioned above, CDC WONDER 
does not rely on the death count less than 20. They considered it as statistically unreliable based 
on a relative standard error of 23 percent or more. However, this study was designed by county 
with a specific underlying reason, so quite a few counties are likely to have small numbers of 
deaths. If a county has low population, the number of deaths less than 20 could be meaningful. 
Thus, I re-calculated the mortality with raw data and included those counties labeled unreliable. 
Moreover, because of confidentiality constraints, they suppressed the data when the count is less 
than 10 (Centers for Disease Control and Prevention, 2018). Consequently, the amount of data 
obtained was less than the actual state overall counts. The state-level death counts were much 
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greater than what I actually extracted. Therefore, a selection bias threat exists because higher 
population counties are more likely to be posted. 
Thirdly, this study did not account for some policies that could affect the result. KyHB1 
included a pain management facility regulation in addition to the use mandate. The PDMP could 
encompass abusive prescription behaviors from those clinics, but it is difficult to account on the 
sole effect of PDMP. Also, alcohol-related tax policies are not included, which are another factor 
causing behavior change in alcohol use.  
Finally, this analysis cannot be generalized to other states, nation-wide level, individual-
level, or population under age 18. Also, it does not present long-term effect of the policy change.  
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Conclusion and Policy Recommendation 
 
 In conclusion, prescription opioid access restriction did not have a statistically significant 
substitution effect of alcohol-induced mortality among adults. This is one of the first studies 
assessing adverse events of PDMPs, especially about unintended consequences of alcohol-
induced death. In addition, this analysis did not find alcohol sales policy to be a significant 
variable in evaluating the relationship between the program and alcohol-induced mortality. 
For these reasons, I recommend retaining the mandate use feature in Kentucky PDMP 
and evaluating the findings with further studies as follow: 
• Evaluate using other outcomes such as age-adjusted mortality, morbidity, and 
drunken driving caused deaths/crashes. 
• Analyze using individual-level deidentified death report data. 
• Expand the range of population (adolescent) and region (other states with mandatory 
use laws). 
• Assess long-term effects of PDMPs on alcohol-related outcomes. 
• Investigate potential urban-rural disparities on alcohol-related outcomes after 
adopting the revised PDMP in Kentucky. 
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